Darbavanacin has antibacterial activity against G+ bacteria including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive staphylococcus aureus (MSSA), coagulase negative staphylococcus (CoNS), streptococcus, etc. It is active against G+ resistant pathogens including penicillin - and ceftriaxone resistant Streptococcus pneumoniae, Teicoranin insensitive CoNS, and non-VANA enterococcus. It is also active against G+ anaerobic bacteria. Dabavacin has unique pharmacokinetic properties and can be administered at weekly intervals. At present, Dabavacin has achieved good results in the treatment of catheter-associated blood-borne infections and skin and soft tissue infections. It has excellent antibacterial activity and safety in vivo, and is an ideal second-generation glycopeptide antibiotic.